Clinical Trials Browser

sargramostim × Clear all

NCT01857934 2026-04-16

Therapy for Children With Advanced Stage Neuroblastoma

Phase 2 Completed

153 enrolled 12 charts

Neuroblastoma

NCT04237623 2026-04-16

GM-CSF With Post-Transplant Cyclophosphamide

Phase 2 Recruiting

Transplant-Related Hematologic Malignancy

NCT07437963 2026-04-15

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

Phase 1/2 Not yet recruiting

Neuroblastoma, Ganglioneuroblastoma

NCT02339571 2026-04-13

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

Phase 2/3 Active not recruiting

Melanoma

NCT03786783 2026-04-13

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Phase 2 Active not recruiting

42 enrolled 12 charts

Ganglioneuroblastoma

NCT07078604 2026-04-07

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT05242965 2026-04-03

A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

5 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05544968 2026-04-03

Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

Phase 1 Recruiting

LymphoidOther hematologic neoplasm

Hodgkin Disease, Leukemia, Lymphoma, Neoplasms, Recurrence, Lymphoma, Large-Cell, Anaplastic

NCT02455557 2026-03-30

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Phase 2 Active not recruiting

66 enrolled 11 charts

Glioblastoma, Gliosarcoma

NCT07169617 2026-03-30

Testing the SurVaxM Vaccine for Lung Cancer Prevention

Phase 2 Not yet recruiting

Lung Neoplasms

NCT06450041 2026-03-23

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Phase 2 Recruiting

Neuroblastoma

NCT05269381 2026-03-12

PNeoVCA

Phase 1/2 Recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06202066 2026-03-11

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Phase 2 Recruiting

Adenoma, Islet Cell

NCT00026312 2026-03-05

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

Phase 3 Completed

1,449 enrolled 17 charts

Neuroblastoma

NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Phase 3 Recruiting

Neuroblastoma, Ganglioneuroblastoma

NCT03794349 2026-02-18

Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

Phase 2 Active not recruiting

94 enrolled 14 charts

Neuroblastoma

NCT06528496 2026-02-10

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

Phase 2 Recruiting

Neuroblastoma

NCT03879694 2026-02-06

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

Phase 1 Completed

Adenoma, Islet Cell

NCT01391962 2026-02-02

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Phase 2 Completed

34 enrolled 22 charts

Sarcoma, Alveolar Soft Part

NCT06626516 2025-11-28

Tebentafusp-tebn With LDT in Metastatic UM

Phase 1/2 Recruiting

Uveal Melanoma, Melanoma

NCT01134614 2025-11-25

Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Phase 2 Active not recruiting

245 enrolled 8 charts

Melanoma

NCT04385277 2025-10-27

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

Phase 2 Active not recruiting

41 enrolled 13 charts

Neuroblastoma, Ganglioneuroblastoma

NCT00669734 2025-10-24

Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery

Phase 1 Active not recruiting

Gastrointestinal

Locally Advanced Pancreatic Adenocarcinoma

NCT05455658 2025-10-24

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT04229979 2025-10-01

REGAL

Phase 3 Active not recruiting

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT07027748 2025-07-14

Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma

Phase 1 Recruiting

Neuroblastoma

NCT04040231 2025-05-13

Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma

Phase 1 Completed

GenitourinaryOther solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma, Wilms Tumor

NCT04211675 2025-05-13

STING

Phase 1/2 Recruiting

Neuroblastoma

NCT02334865 2025-05-11

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Phase 1 Active not recruiting

Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

NCT03600350 2025-05-09

pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer

Phase 2 Active not recruiting

19 enrolled 10 charts

Prostatic Neoplasms

NCT03332667 2025-04-16

MIBG With Dinutuximab +/- Vorinostat

Phase 1 Completed

45 enrolled 16 charts

Neuroblastoma

NCT00436254 2025-04-06

Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer

Phase 1 Completed

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms

NCT01903330 2025-03-05

ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

Phase 2 Active not recruiting

Glioblastoma, Gliosarcoma

NCT04382664 2025-01-14

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

Phase 2 Completed

156 enrolled 11 charts

Melanoma

NCT01784913 2024-12-16

UV1/hTERT2012P

Phase 1/2 Completed

Neoplasms, Prostatic Neoplasms

NCT01789099 2024-12-16

UV1-hTERT2012L

Phase 1/2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02275416 2024-12-16

Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma

Phase 1/2 Completed

Melanoma

NCT01266083 2024-11-19

WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

Phase 2 Completed

22 enrolled 8 charts

LymphoidOther hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03761914 2024-11-19

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Phase 1/2 Completed

26 enrolled 14 charts

BreastGastrointestinalGynecologicOther hematologic neoplasmThoracic

Ovarian Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT01827137 2024-09-19

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

Phase 1/2 Completed

20 enrolled 9 charts

GenitourinaryPlasma cell

Multiple Myeloma, Wilms Tumor

NCT02780401 2024-09-19

WOKVAC

Phase 1 Completed

32 enrolled 13 charts

Breast Neoplasms

NCT04013672 2024-08-28

Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence

Phase 2 Completed

41 enrolled 15 charts

Glioblastoma

NCT04739618 2024-07-23

Metastatic Solid Cancer Clinical Trial

Phase 2 Active not recruiting

Neoplasm Metastasis

NCT05771584 2024-07-10

Conerstone3

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT05163223 2024-06-17

Cornerstone001

Phase 2 Terminated

Breast Neoplasms

NCT05101356 2024-05-21

A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma

Phase 1/2 Recruiting

Adenocarcinoma, Neoplasm Metastasis

NCT04713371 2024-05-09

A Phase 2 Trial for Patients With Metastatic Solid Cancer

Phase 2 Active not recruiting

Neoplasm Metastasis

NCT02728102 2024-05-07

Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)

Phase 2 Completed

203 enrolled 25 charts

Hematologic Diseases, Multiple Myeloma

NCT02169609 2024-04-22

Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma

Phase 2 Completed

Neuroblastoma, Neoplasm, Residual

NCT03927222 2024-04-08

I-ATTAC

Phase 2 Terminated

6 enrolled 7 charts

Glioblastoma, Tetanus